C4 Therapeutics, Inc.
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a CCCC research report →
Range $7 – $7
Price Chart
About the company
C4 Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on discovering and developing innovative therapeutic candidates. Its core strategy involves degrading proteins implicated in disease, addressing a range of conditions including cancer, neurodegenerative disorders, and other illnesses.
- CEO
- Andrew J. Hirsch
- IPO
- 2020
- Employees
- 104
- HQ
- Watertown, MA, US
Get TickerSpark's AI analysis on CCCC
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Similar companies
Peers in the same neighborhood.
- Market Cap
- $325.67M
- P/E
- -3.39
- Fwd P/E
- 3.41
- PEG
- -0.03
- P/S
- 9.93
- P/B
- 1.46
- EV/EBITDA
- -3.72
- Div Yield
- 0.00%
- Gross Margin
- 94.42%
- Op Margin
- -315.86%
- Net Margin
- -282.22%
- ROE
- -37.71%
- ROIC
- -34.31%
Latest fiscal year · YoY change
- Revenue
- $35.95M+1.0%
- Gross Profit
- $27.97M-21.4%
- Op Income
- $-104,489,000
- Net Income
- $-104,994,000+0.3%
- EPS
- $-1.27+16.4%
- OCF Growth
- -51.5%
- FCF Growth
- -52.0%
- 52W High
- $5.17
- 52W Low
- $1.69
- 50D MA
- $3.05
- 200D MA
- $3.26
- Beta
- 3.16
- RSI (14)
- 33
- Avg Volume
- 2.54M
No earnings-call transcripts are available for CCCC yet.
- Free Float
- 78.3%
- Shares Outstanding
- 131.32M
- Float Shares
- 102.86M
of shares held by institutions
158 13F filers
Buy/sell ratio 2.00. Sells can include pre-scheduled 10b5-1 plan sales, not just discretionary selling.
Top institutional holders
Largest 13F positions, with quarter-over-quarter change.
| Holder | Shares | Δ Quarter |
|---|---|---|
| Morgan Stanley | 8.87M | ▲ 5.30K |
| Blackrock, Inc. | 8.18M | ▲ 283.21K |
| Ra Capital Management, L.P. | 8.00M | 0 |
| Lynx1 Capital Management LP | 7.33M | ▲ 327.79K |
| Squadron Capital Management LLC | 7.20M | ▲ 4.95M |
| Bain Capital Life Sciences Investors, LLC | 7.17M | 0 |
| Jpmorgan Chase & Co | 4.70M | ▼ 50.44K |
| Vanguard Capital Management LLC | 4.58M | ▲ 163.77K |
| Vanguard Group Inc | 4.38M | ▲ 1.19M |
| Citadel Advisors LLC | 4.19M | ▲ 1.68M |
| Goldman Sachs Group Inc | 3.53M | ▲ 1.14M |
| Two Sigma Investments, LP | 3.47M | ▲ 434.07K |
Held by 131 ETFs
Biggest fund positions in CCCC by dollar value.
Recent insider transactions
Who's buying, who's selling, and how much.
| Date | Insider | Type | Shares |
|---|---|---|---|
| Nov 12, 26 | Adams Kendra | sell | 45,173 |
| Oct 1, 26 | Anderson Kenneth Carl | other | 3,662 |
| Oct 1, 26 | GROGAN DONNA ROY | other | 4,618 |
| Sep 18, 26 | Adams Kendra | other | 6,250 |
| Sep 18, 26 | Adams Kendra | other | 2,775 |
| Jul 10, 26 | REYNO LEONARD | other | 15,325 |
| Jul 10, 26 | REYNO LEONARD | other | 7,397 |
| Jul 1, 26 | Anderson Kenneth Carl | other | 2,650 |
| Jul 1, 26 | GROGAN DONNA ROY | other | 3,341 |
| Jun 24, 26 | Hughes Owen | other | 62,000 |
A “Sell” may be a pre-scheduled 10b5-1 plan sale rather than a discretionary decision — read insider selling with that in mind.
Our CCCC coverage
Recent articles, reports, and earnings notes.
Want a deeper read on CCCC?
Generate a full analyst-grade report — bull/bear case, price targets, valuation depth, and a complete financial breakdown.
Is C4 Therapeutics (CCCC) Outperforming Other Medical Stocks This Year?
zacks.com · Nov 18
C4 Therapeutics, Inc. (CCCC) Reports Q3 Loss, Lags Revenue Estimates
zacks.com · Nov 5
C4 Therapeutics Reports Third Quarter 2026 Financial Results and Recent Business Highlights
globenewswire.com · Nov 5
C4 Therapeutics to Participate in Upcoming November Investor Conferences
globenewswire.com · Nov 3
C4 Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
globenewswire.com · Nov 2
C4 Therapeutics, Inc. (CCCC) Expected to Beat Earnings Estimates: What to Know Ahead of Q3 Release
zacks.com · Oct 29
C4 Therapeutics Unveils Expansion of Discovery Platform Capabilities Utilizing Target-Centric Approach to Accelerate the Identification of Novel Molecular Glue Degraders
globenewswire.com · Oct 29
Tenaya Therapeutics (NASDAQ:TNYA) and C4 Therapeutics (NASDAQ:CCCC) Financial Survey
defenseworld.net · Oct 22
Headlines from third-party outlets — TickerSpark isn't affiliated with these sources.
